BlossomHill Therapeutics, Inc. Stock: price and insider trades · United States
2 insiders bought €17.3M of shares over the last 90 days, the latest by ORBIMED ADVISORS LLC, filed 12 Aug 2026.
BlossomHill Therapeutics, Inc.: what insiders have been doing
BlossomHill Therapeutics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). 9 insiders have disclosed 20 filings since 9 November 2025.
No insider sold shares on the market over the period. Instead, the filings list 6 purchases totalling €13.1M, made by 5 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 4 senior executives and 1 finance chief. At €8.7M, the purchase published on 12 August 2026 by Orbimed Advisors LLC is the largest of the period (2.5% of market cap).
In the case of 5 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase dates back some time: it was published 88 days ago, on 12 August 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 20 filings here. Looking back to 2026, when coverage begins, insiders filed 6 purchases and no sales.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- +33.0%Entry US$16.35 · Close at T+30 US$21.74
- +30.2%Entry US$16.24 · Close at T+30 US$21.15
- +30.2%Entry US$16.24 · Close at T+30 US$21.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BlossomHill Therapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$35.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 625,000 shares@ US$16.001.57% mcap100.0% of flowCommon StockSEC:0000947871-26-000784:2Canonical exit: 8 Nov 2026 (T+90)
- 1,039,996 sharesCommon StockSEC:0000947871-26-000784:0
- 1,049,283 sharesCommon StockSEC:0000947871-26-000784:1
- 1,039,996 sharesCommon StockSEC:0000947871-26-000785:0
- 1,049,283 sharesCommon StockSEC:0000947871-26-000785:1
- 625,000 shares@ US$16.001.57% mcap100.0% of flowCommon StockSEC:0000947871-26-000785:2Canonical exit: 8 Nov 2026 (T+90)
- 578,524 sharesCommon StockSEC:0001840599-26-000003:0
- 1,599,993 sharesCommon StockSEC:0001231919-26-000852:0
- 1,701,541 sharesCommon StockSEC:0001231919-26-000852:1
- 1,600,682 sharesCommon StockSEC:0001772233-26-000005:0
- 22,687 sharesCommon StockSEC:0002143905-26-000003:2
- 113,435 sharesCommon StockSEC:0001772233-26-000005:1
- 124,779 sharesCommon StockSEC:0001772233-26-000005:2
- 1,600,682 sharesCommon StockSEC:0001772259-26-000005:0
- 113,435 sharesCommon StockSEC:0001772259-26-000005:1
- 124,779 sharesCommon StockSEC:0001772259-26-000005:2
- 312,500 shares@ US$16.000.78% mcap100.0% of flowCommon StockSEC:0001231919-26-000852:2Canonical exit: 8 Nov 2026 (T+90)
- 6,000 shares@ US$16.000.015% mcap100.0% of flowCommon StockSEC:0001478916-26-000015:0Canonical exit: 8 Nov 2026 (T+90)
- 700 shares@ US$16.000.0018% mcap100.0% of flowCommon StockSEC:0001678152-26-000003:0Canonical exit: 8 Nov 2026 (T+90)
- 2,500 shares@ US$15.800.0062% mcap52.9% of flowCommon StockSEC:0002143905-26-000003:0Canonical exit: 5 Nov 2026 (T+90)
- 2,200 shares@ US$16.000.0055% mcap47.1% of flowCommon StockSEC:0002143905-26-000003:1Canonical exit: 8 Nov 2026 (T+90)
21 of 21 declarations
About BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc. is a company focused on developing innovative treatments for chronic diseases. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
